The shares are listed on the Nasdaq Global Market

Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering program by Affimed N.V. of up to $100 million gross sales price of its common shares. The common shares are listed on the Nasdaq Global Market under the symbol “AFMD.”

Based in Heidelberg, Germany, Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE.

The Davis Polk capital markets team included partner Derek Dostal, counsel Dan Gibbons and associate Taeo I. Carse. The tax team included partner Patrick E. Sigmon and associate Benjamin Helfgott. The intellectual property and technology transactions team included partner David R. Bauer and associate Jesse L. Hallock. All members of the Davis Polk team are based in the New York office.